CTOs on the Move

NexImmune

www.neximmune.com

 
NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIM™ technology.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

NexImmune raised $126.5M on 02/17/2021

Similar Companies

Somaxon Pharmaceuticals, Inc.

Somaxon Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

CTI BioPharma

CTI was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. We strive to do business better than other biopharmaceutical companies. Better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. A willingness to push the limits to achieve challenging goals is the essential attribute that sets CTI employees apart.

Civetta Therapeutics

Civetta Therapeutics was founded by William Sellers (Broad Institute and Dana-Farber Cancer Institute) and Eric Fischer (Dana Farber Cancer Institute and Harvard Medical School) to advance new medicines through small molecule intervention targeting propeller domains with the goal of developing important therapeutics for cancer and other indications.

NMD Pharma

NMD Pharma A/S is a clinical-stage biotech company developing a first-in-class platform of small molecule therapies selectively targeting the skeletal muscle chloride ion channel (ClC-1) for the treatment of severe neuromuscular disorders. The Company was incorporated as a spin-off from Aarhus University, Denmark in 2015 and was founded on more than 15 years of muscle physiology research with a focus on regulation of skeletal muscle excitability under physical activity. NMD Pharma has built a world-leading muscle electrophysiology platform leveraging the in-depth know-how of muscle physiology and muscular disorders, small molecule modulators, enabling technologies and tools as well as in vivo pharmacology models for discovering and developing proprietary modulators of neuromuscular function. NMD Pharma received initial seed financing in 2016 and has since raised ~€155 million from investors including Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, Roche Venture Fund, and Jeito Capital.

Biocompare

Biocompare is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.